Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease

Molecules

Volumn 21, Issue 4, 2016, Pages

  Jones, Mike ^a   Wang, Jun ^a   Harmon, Shona ^a   Kling, Beata ^b   Heilmann, Jörg ^b   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Alzheimer's disease; Antioxidant; Cholinesterase inhibitor; Hybrid; Neuroprotection

Indexed keywords

ANTIOXIDANT; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; ESTER;

ALZHEIMER DISEASE; ANIMAL; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; HIPPOCAMPUS; MOUSE; NERVE CELL; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BUTYRYLCHOLINESTERASE; CARBAMATES; CELL LINE; CHOLINESTERASE INHIBITORS; ESTERS; HIPPOCAMPUS; MICE; MOLECULAR STRUCTURE; NEURONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84966351747     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules21040440     Document Type: Article

References (31)

1. Bertram, L.; Tanzi, R.E. The genetic epidemiology of neurodegenerative disease. J. Clin. Investig. 2005, 115, 1449-1457. [CrossRef] [PubMed]
2. Bartus, R.T.; Dean, R.L., 3rd; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217, 408-414. [CrossRef] [PubMed]
3. Deardorff, W.J.; Feen, E.; Grossberg, G.T. The use of cholinesterase inhibitors across all sages of Alzheimer's Disease. Drugs Aging 2015, 32, 537-547. [CrossRef] [PubMed]
4. Tan, C.C.; Yu, J.T.; Wang, H.F.; Tan, M.S.; Meng, X.F.; Wang, C.; Jiang, T.; Zhu, X.C.; Tan, L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease systematic review and meta-analysis. J. Alzheimers Dis. 2014, 41, 615-631. [PubMed]
5. Brus, B.; Ko?ak, U.; Turk, S.; Pi?lar, A.; Coquelle, N.; Kos, J.; Stojan, J.; Colletier, J.P.; Gobec, S. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J. Med. Chem. 2014, 57, 8167-8179. [CrossRef] [PubMed]
6. Huang, G.; Kling, B.; Darras, F.H.; Heilmann, J.; Decker, M. Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine. Eur. J. Med. Chem. 2014, 81, 15-21. [CrossRef] [PubMed]
7. Chen, X.; Tikhonova, I.G.; Decker, M. Probing the mid-gorge of cholinesterases with spacer-modified bivalent quinazolinimines leads to highly potent and selective butyrylcholinesterase inhibitors. Bioorg. Med. Chem. 2011, 19, 1222-1235. [CrossRef] [PubMed]
8. Maurice, T.; Strehaiano, M.; Siméon, N.; Bertrand, C.; Chatonnet, A. Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse. Behav. Brain Res. 2016, 296, 351-360. [PubMed]
9. Greig, N.H.; Utsuki, T.; Ingram, D.K.; Wang, Y.; Pepeu, G.; Scali, C.; Yu, Q.S.; Mamczarz, J.; Holloway, H.W.; Giordano, T.; et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc. Natl. Acad. Sci. USA 2005, 102, 17213-17218. [CrossRef] [PubMed]
10. Mesulam, M.M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E.G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002, 110, 627-639. [CrossRef]
11. Montanari, S.; Bartolini, M.; Neviani, P.; Belluti, F.; Gobbi, S.; Pruccoli, L.; Tarozzi, A.; Falchi, F.; Andrisano, V.; Miszta, P.; et al. Multitarget Strategy to Address Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and Computational Studies of Coumarin-Based Derivatives. ChemMedChem 2015. [CrossRef] [PubMed]
12. Decker, M. Recent advances in the development of hybrid molecules/designed multiple compounds with antiamnesic properties. Mini Rev. Med. Chem. 2007, 3, 221-229. [CrossRef]
13. Koufaki, M.; Detsi, A.; Kiziridi, C. Multifunctional lipoic acid conjugates. Curr. Med. Chem. 2009, 16, 4728-4742. [CrossRef] [PubMed]
14. Perry, G.; Cash, A.D.; Smith, M.A. Alzheimer Disease and Oxidative Stress. J. Biomed. Biotechnol. 2002, 2, 120-123. [CrossRef] [PubMed]
15. Park, S.; Karunakaran, U.; Jeoung, N.H.; Jeon, J.H.; Lee, I.K. Physiological effect and therapeutic application of alpha lipoic acid. Curr. Med. Chem. 2014, 21, 3636-3645. [CrossRef] [PubMed]
16. Decker, M.; Kraus, B.; Heilmann, J. Design, synthesis and pharmacological evaluation of hybrid molecules out of quinazolinimines and lipoic acid lead to highly potent and selective butyrylcholinesterase inhibitors with antioxidant properties. Bioorg. Med. Chem. 2008, 16, 4252-4261. [CrossRef] [PubMed]
17. Rosini, M.; Simoni, E.; Bartolini, M.; Tarozzi, A.; Matera, R.; Milelli, A.; Hrelia, P.; Andrisano, V.; Bolognesi, M.L.; Melchiorre, C. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem. 2011, 46, 5435-5442. [CrossRef] [PubMed]
18. Sultana, R. Ferulic acid ethyl ester as a potential therapy in neurodegenerative disorders. Biochim. Biophys. Acta 2012, 1822, 748-752. [CrossRef] [PubMed]
19. Mori, T.; Koyama, N.; Guillot-Sestier, M.V.; Tan, J.; Town, T. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and Alzheimer-like pathology in transgenic mice. PLoS ONE 2013, 8, e55774.
20. Yan, J.J.; Jung, J.S.; Kim, T.K.; Hasan, A.; Hong, C.W.; Nam, J.S.; Song, D.K. Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease. Biol. Pharm. Bull. 2013, 36, 140-143. [CrossRef] [PubMed]
21. Benchekroun, M.; Bartolini, M.; Egea, J.; Romero, A.; Soriano, E.; Pudlo, M.; Luzet, V.; Andrisano, V.; Jimeno, M.L.; López, M.G.; et al. Novel tacrine-grafted Ugi adducts as multipotent anti-Alzheimer drugs: A synthetic renewal in tacrine-ferulic acid hybrids. ChemMedChem 2015, 10, 523-539. [CrossRef] [PubMed]
22. Carolan, C.G.; Dillon, G.P.; Gaynor, J.M.; Reidy, S.; Ryder, S.A.; Khan, D.; Marquez, J.F.; Gilmer, J.F. Isosorbide-2-carbamate Esters: Potent and Selective Butyrylcholinesterase Inhibitors. J. Med. Chem. 2008, 51, 6400-6409. [CrossRef] [PubMed]
23. Dillon, G.P.; Gaynor, J.M.; Khan, D.; Carolan, C.G.; Ryder, S.A.; Marquez, J.F.; Reidy, S.; Gilmer, J.F. Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg. Med. Chem. 2010, 18, 1045-1053. [CrossRef] [PubMed]
24. Carolan, C.G.; Dillon, G.P.; Khan, D.; Ryder, S.A.; Gaynor, J.M.; Reidy, S.; Marquez, J.F.; Jones, M.; Holland, V.; Gilmer, J.F. Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J. Med. Chem. 2010, 53, 1190-1199. [PubMed]
25. Carolan, C.G.; Gaynor, J.M.; Dillon, G.P.; Khan, D.; Ryder, S.A.; Reidy, S.; Gilmer, J.F. Novel isosorbide di-ester compounds as inhibitors of acetylcholinesterase. Chem. Biol. Interact. 2008, 175, 293-297. [CrossRef] [PubMed]
26. Kling, B.; Bücherl, D.; Palatzky, P.; Kling, B.; Bücherl, D.; Palatzky, P.; Matysik, F.M.; Decker, M.; Wegener, J.; Heilmann, J. Flavonoids, flavonoid metabolites, and phenolic acids inhibit oxidative stress in the neuronal cell line HT-22 monitored by ECIS and MTT assay: A comparative study. J. Nat. Prod. 2014, 77, 446-454. [CrossRef] [PubMed]
27. Tan, S.; Wood, M.; Maher, P. Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J. Neurochem. 1998, 71, 95-105. [CrossRef]
28. Ishige, K.; Schubert, D.; Sagara, Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic. Biol. Med. 2001, 30, 433-446. [CrossRef]
29. Dávalos, A.; Gómez-Cordovés, C.; Bartolomé, B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J. Agric. Food Chem. 2004, 52, 48-54. [CrossRef] [PubMed]
30. Vogel, S.; Ohhmayer, S.; Brunner, G.; Heilmann, J. Natural and non-natural prenylated chalcones: Synthesis, cytotoxicity and anti-oxidative activity. Bioorg. Med. Chem. 2008, 16, 4286-4293. [PubMed]
31. Fang, L.; Kraus, B.; Lehmann, J.; Heilmann, J.; Zhang, Y.; Decker, M. Design and synthesis of tacrine-ferulic acid hybrids as multi-potent anti-Alzheimer drug candidates. Bioorg. Med. Chem. Lett. 2008, 18, 2905-2909. [PubMed]